Circulating tumor cells are correlated with disease progression and treatment response in an orthotopic hepatocellular carcinoma model

Hepatocellular carcinoma (HCC) is a highly malignant tumor characterized by rapid progression, poor prognosis, and frequent hematogenous metastasis. A minimally invasive diagnostic biomarker that can predict disease progression and treatment response would be of extraordinary benefit. Therefore, we have investigated whether the number of circulating tumor cells (CTCs) is correlated with disease progression and treatment response in HCC. Here we report that the number of CTCs, monitored by in vivo flow cytometry (IVFC), is strongly correlated with disease progression and treatment response in a highly metastatic orthotopic nude mouse model of green fluorescent protein (GFP)‐labeled HCC. Sorafenib treatment reduces the number of CTCs significantly. The decreased number of CTCs is consistent with low lung metastasis. This study has demonstrated a considerable clinical value of CTCs as a biomarker in predicting disease progression and monitoring therapeutic efficacy in patients with HCC. © 2015 International Society for Advancement of Cytometry

[1]  Charles P. Lin,et al.  In vivo flow cytometer for real-time detection and quantification of circulating cells. , 2004, Optics letters.

[2]  H. Bismuth,et al.  Real-Time Quantification of AFP mRNA to Assess Hematogenous Dissemination After Transarterial Chemoembolization of Hepatocellular Carcinoma , 2003, Annals of surgery.

[3]  J. Llovet,et al.  Updated treatment approach to hepatocellular carcinoma , 2005, Journal of Gastroenterology.

[4]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[5]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[6]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[7]  A. Tannapfel,et al.  Prospective evaluation of circulating hepatocytes by alpha-fetoprotein messenger RNA in patients with hepatocellular carcinoma. , 2002, Surgery.

[8]  Axel Mosig,et al.  Circulation times of prostate cancer and hepatocellular carcinoma cells by in vivo flow cytometry , 2011, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[9]  M. Makuuchi,et al.  α‐Fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: A prospective study , 2002 .

[10]  Wei-Zhong Wu,et al.  Real-time monitoring of rare circulating hepatocellular carcinoma cells in an orthotopic model by in vivo flow cytometry assesses resection on metastasis. , 2012, Cancer research.

[11]  J. Llovet,et al.  Systematic review: evidence‐based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials , 2006, Alimentary pharmacology & therapeutics.

[12]  S. Wilhelm,et al.  Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. , 2006, Cancer research.

[13]  S. Fan,et al.  Prediction of Posthepatectomy Recurrence of Hepatocellular Carcinoma by Circulating Cancer Stem Cells: A Prospective Study , 2011, Annals of surgery.

[14]  W. Lau,et al.  Hematogenous dissemination of hepatocytes and tumor cells after surgical resection of hepatocellular carcinoma: a quantitative analysis. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  Xunbin Wei,et al.  In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment , 2005, Nature.

[16]  Yu Zhang,et al.  Isolation of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Using a Novel Cell Separation Strategy , 2011, Clinical Cancer Research.

[17]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[18]  Wei Wu,et al.  Characteristics of hepatic igf-ii expression and monitored levels of circulating igf-ii mRNA in metastasis of hepatocellular carcinoma. , 2010, American journal of clinical pathology.

[19]  S. Cheung,et al.  Albumin mRNA in Plasma Predicts Post-Transplant Recurrence of Patients With Hepatocellular Carcinoma , 2008, Transplantation.

[20]  S. Ye,et al.  New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis , 1999, British Journal of Cancer.

[21]  Joong-Won Park,et al.  Alpha-fetoprotein and human telomerase reverse transcriptase mRNA levels in peripheral blood of patients with hepatocellular carcinoma , 2009, Journal of Cancer Research and Clinical Oncology.

[22]  H. Bismuth,et al.  Prospective evaluation of circulating hepatocytes by alpha-fetoprotein mRNA in humans during liver surgery. , 1997, Annals of surgery.

[23]  Masato Takahashi,et al.  AFP mRNA Detected in Bone Marrow by Real-Time Quantitative RT-PCR Analysis Predicts Survival and Recurrence After Curative Hepatectomy for Hepatocellular Carcinoma , 2006, Annals of surgery.

[24]  S. Bae,et al.  High expression of Snail mRNA in blood from hepatocellular carcinoma patients with extra-hepatic metastasis , 2009, Clinical & Experimental Metastasis.

[25]  Michael Morse,et al.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Imamura,et al.  Hematogenous spreading of hepatocellular carcinoma cells: Possible participation in recurrence in the liver , 1997, Hepatology.

[27]  K. Shirabe,et al.  Perioperative change in albumin messenger RNA levels in patients with hepatocellular carcinoma , 1998, Hepatology.

[28]  Jia Fan,et al.  Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance , 2011, Journal of Cancer Research and Clinical Oncology.

[29]  Xin Wei Wang,et al.  Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. , 2006, Cancer cell.

[30]  S. Kar,et al.  Detection of liver cells in peripheral blood of patients with advanced‐stage hepatocellular carcinoma , 1995, Hepatology.

[31]  S. Kar,et al.  Detection of liver cells in peripheral blood of patients with advanced-stage hepatocellular carcinoma , 1995 .

[32]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[33]  R. Fugger,et al.  Lack of specificity of albumin‐mRNA–positive cells as a marker of circulating hepatoma cells , 1997, Hepatology.

[34]  Yao-ren Hu,et al.  Detecting AFP mRNA in peripheral blood of the patients with hepatocellular carcinoma, liver cirrhosis and hepatitis. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[35]  Jin Guo,et al.  Circulation times of hepatocellular carcinoma cells by in vivo flow cytometry , 2010 .

[36]  L. Lumeng,et al.  A reproducible rat liver cancer model for experimental therapy: introducing a technique of intrahepatic tumor implantation. , 1992, The Journal of surgical research.

[37]  M. Monden,et al.  Association Between Recurrence of Hepatocellular Carcinoma and α-Fetoprotein Messenger RNA Levels in Peripheral Blood , 2005, Surgery Today.